MHRA issues new batch of Drug Safety Update notices

MHRA issues new batch of Drug Safety Update notices

November 28 2017 The medicines regulator has issued four Drug Safety Updates relating to...

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

October 31 2017 The medicines regulator has issued four drug safety updates (DRU) relating to...

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

PPIs may add to liver disease problems in people with alcohol dependency, suggests study

October 17 2017 Protein pump inhibitors could supress stomach acid secretion to the extent it...

Pregnant women are not always informed of risks associated with sodium valproate

Pregnant women are not always informed of risks associated with sodium valproate

September 26 2017 Almost a fifth of women with epilepsy (18%) who take sodium valproate are not...

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

September 4 2017 Ibuprofen is associated with increased blood pressure and hypertension compared...

  • MHRA issues new batch of Drug Safety Update notices

    MHRA issues new batch of Drug Safety Update notices

    Tuesday, 28 November 2017 09:47
  • MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    MHRA issues DRUs covering gabapentin, methylprednisolone, clozapine and isotretinoin

    Tuesday, 31 October 2017 20:03
  • PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    PPIs may add to liver disease problems in people with alcohol dependency, suggests study

    Tuesday, 17 October 2017 14:27
  • Pregnant women are not always informed of risks associated with sodium valproate

    Pregnant women are not always informed of risks associated with sodium valproate

    Tuesday, 26 September 2017 14:14
  • Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Monday, 04 September 2017 15:12

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a alert imageNovember 28 2017

The medicines regulator has issued four Drug Safety Updates relating to gentamicin, quinine, oral tacrolimus preparations, and anti-epileptic drugs.

The MHRA’s gentamicin DSU advises about possible high levels of histamine being present in several different batches of gentamicin injections from different marketing authorisation holders. The manufacturing process of the active pharmaceutical ingredient gentamicin may include higher levels of histamine as a residual from the manufacturing process.

Health professionals are advised to monitor patients for signs of histamine-related adverse effects, including anaphylaxis-type reactions, hypotensive reactions, or increased heart rate. Caution should be used in treating patients with gentamicin, especially if they are also using other drugs which may stimulate histamine release.

The DSU on quinine is a reminder of the dose-dependent effect prolonging the QT-interval in heart rhythm. It says the drug “should be used with caution in patients with risk factors for QT prolongation or in those with atrioventricular block.”

Prescribers need to consider conditions that may impact on QT prolongation such as cardiac disease or electrolyte balance, atrioventricular block or concomitant use of other drugs which can affect the QT interval. Patients requiring phenobarbital or carbamazepine need close monitoring as serum levels could become toxic.

The third DSU advises that changes between oral tacrolimus preparations need to be managed carefully, as “inadvertent switching between tacrolimus products has been associated with reports of toxicity and graft rejection …  tacrolimus has a narrow therapeutic index, and even minor differences in blood levels have the potential to cause graft rejection reactions or toxicity.”

A DSU on oral tacrolimus was first issued in 2012, but the advisory has been reissued as new oral tacrolimus products have been licensed or are now being launched into the market.

The final DSU from relates to considerations about switching between different manufacturers’ anti-epileptic drugs. Advice issued in 2013 still stands, relating to the three risk-based categories of anti-epileptics and changing the brand/manufacturer. Health professionals are now being advised that they should additionally take into account the patient’s perceptions about switching brands.

Links:
MHRA DSU on gentamicin            
MHRA DSU on quinine sulphate                  
MHRA DSU on tacrolimus            
MHRA DSU on anti-epilepsy drugs

Clinical News

December 7 2017 LloydsPharmacy has announced a new scheme to give patients the option to receive some hospital treatments closer to home. 
December 7 2015 Pharmacists in Scotland have been asked to share their views on what politicians need to be made aware of ahead of the Scottish Parliament elections in 2016. The Royal Pharmaceutical Society...